Discovery of 4-aminochalcone-based dual α-glucosidase and aldose reductase inhibitors: in vitro, in vivo, and in silico studies
Ehsan Ullah Mughal, Nafeesa Naeem, Songül Bayrak, Namık Kılınç, Bushra Shakoor, Magdi E. A. Zaki, Maher Fathalla, Sobhi M. Gomha, Amina Sadiq, Züleyha Almaz · 2026
Read Discovery of 4-aminochalcone-based dual α-glucosidase and aldose reductase inhibitors: in vitro, in vivo, and in silico studies by Ehsan Ullah Mughal, Nafeesa Naeem, Songül Bayrak, Namık Kılınç, Bushra Shakoor, Magdi E. A. Zaki, Maher Fathalla, Sobhi M. Gomha, Amina Sadiq, Züleyha Almaz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13505551.txt.
Description
One drug slowing two diabetes enzymes at once could blunt both blood-sugar spikes and long-term damage, and Ehsan Ullah Mughal and co-authors built ten candidate molecules on a chalcone scaffold to try. Lab tests measured each compound against a starch-blocking enzyme and a second enzyme implicated in diabetic complications. The best performers hit the first enzyme at very low doses.
The leaders then went into diabetic rats, where they improved sugar control, body weight, blood fats, and liver markers. Computer docking showed how the molecules grip both enzymes, simulations confirmed the grip holds, and safety screens rated the compounds drug-like. The authors claim the first report of this scaffold against the second enzyme, and offer the family as dual-target leads.
Catalog record
| CREATOR | Ehsan Ullah Mughal, Nafeesa Naeem, Songül Bayrak, Namık Kılınç, Bushra Shakoor, Magdi E. A. Zaki, Maher Fathalla, Sobhi M. Gomha, Amina Sadiq, Züleyha Almaz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 116 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |